Retatrutide vs other GLP-1 peptides: cost comparison Part of determining whether cheap retatrutide is actually a good deal involves comparing it to alternatives
Contraindications, medication interactions, and individual risk factors determine which options are appropriate for you
However, a newer oral agent in development called Orforglipron has shown much better bioavailability and produced around 1415% weight loss in Phase 2 trials, making it nearly comparable to current injectables
adults having obesity, according to the Centers for Disease Control and Prevention
Projected commercial pricing When Eli Lilly eventually brings retatrutide to market, likely in late 2027 or 2028, analysts project a list price of $1,000 to $1,500 per month based on comparable GLP-1 medications like Mounjaro and Ozempic
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Elkin J, et al